Update in version 2021 of CSCO guidelines for colorectal cancer from version 2020

Dong, Caixia; Ding, Yuwei; Weng, Shanshan; Li, Guichao; Huang, Yanqing; Hu, Hanguang; Zhang, Zhen; Zhang, Suzhan; Yuan, Ying

doi:10.21147/j.issn.1000-9604.2021.03.02

Cited by 41 publications

(32 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The further the distance between the tumor and MRF, the better the prognosis (cutoff =7 mm). We noticed that cT3 stage rectal cancer patients had a wide range of 5-year survival rate, but still receive uniform NCRT ( 4 , 22 - 25 ), which leads to the need for prognostic stratification for these patients. Although many studies proposed that EMD of tumor invasion should be used for T3 stage stratification, in our study, we did not observe a significant association between EMD-based T3 substage and prognosis.…”

Section: Discussionmentioning

confidence: 99%

Better prognostic determination of cT3 rectal cancer through measurement of distance to mesorectal fascia: A multicenter study

Zhang

Guo

et al. 2021

Chinese Journal of Cancer Research

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Better prognostic determination of cT3 rectal cancer through measurement of distance to mesorectal fascia: A multicenter study

Zhang

Guo

et al. 2021

Chinese Journal of Cancer Research

View full text Add to dashboard Cite

“…The common clinical therapy plan for patients with rectal cancer in this study was implemented according to the Chinese Society of Clinical Oncology(CSCO) guidelines for colorectal cancer(version 2020) ( 19 ). Laparoscopic-assisted sphincter-saving surgery and robotic-assisted sphincter-saving surgery were the main methods for patients enrolled in this study.…”

Section: Methodsmentioning

confidence: 99%

The Association Between Dietary Intake and Improvement of LARS Among Rectal Cancer Patients After Sphincter-Saving Surgery-A Descriptive Cohort Study

Xia

2022

Front. Surg.

View full text Add to dashboard Cite

BackgroundDietary management was an important strategy for controlling low anterior resection syndrome (LARS) after sphincter-saving surgery, however, the influencing dietary factors of LARS are not completely clear. This study aims at exploring the specific association between perioperative intake of foods and nutrients and the improvement of LARS within the first 6 months after surgery.MethodsThis study applied a prospective cohort design. 210 consecutive patients were admitted in the colorectal surgical ward after the sphincter-saving surgery in a tertiary hospital in China from May to November in 2020. The perioperative food intake was assessed by the food frequency questionnaire, and the bowel symptoms were assessed by the Low Anterior Resection Syndrome Score Scale. The binary logistic regression was used to analyze the collected data.ResultsIt was found out that both the intake of oil before surgery and at 6 months after surgery were significantly associated with the improvement of LARS. The average daily intake of livestock and poultry meats and oil during the first 6 months after sphincter-saving surgery were also associated with the improvement of LARS.ConclusionsThe relationship between the intake of Livestock and poultry meats and oil and the improvement of LARS was significant in this study. It provides evidence for medical staff to make up effective interventions of moderating diet to promote the relief of LARS during the first 6 months after sphincter-saving surgery.

show abstract

“…The FOLFOXIRI regimen has a relatively high DI. Based on the present medical guidelines, the Chinese Society of Clinical Oncology guidelines incorporated FOLFOXIRI into a first-level recommended regimen for patients with potentially resectable mCRC who are suitable for intensive treatment and are positive for RAS/BRAF mutations (18). The National Comprehensive Cancer Network (NCCN) guidelines recommend this regimen for patients with higher performance status scores (19).…”

Section: Three-drug Combination Chemotherapy Regimensmentioning

confidence: 99%

“…The dose of L-OHP, the infusion mode and the dose of 5-FU were adjusted to balance the incidence of adverse reactions and the treatment efficacy. At present, the mFOLFOX-6 regimen is mainly recommended in the guidelines and has become widely accepted in clinical practice (18)(19)(20)(21). The three first-line two-drug regimens are almost equivalent regarding their curative effects and they are frequently used as a back-line treatment or alternative treatment in the clinic.…”

Section: Two-drug Combination Chemotherapy Regimensmentioning

confidence: 99%

Management of chemotherapy dose intensity for metastatic colorectal cancer (Review)

2022

View full text Add to dashboard Cite

Chemotherapy dose intensity is a momentous parameter of antitumor clinical medication. In certain clinical trials, the actual application dose of the chemotherapeutic drugs is frequently different from the prescribed dose. The chemotherapy dose intensity completed in different trials is also variable, which has an impact on the treatment efficacy, disease prognosis and patient safety. When these agents are tested in the population, chemotherapy reduction and delay or failure to complete the planned cycle constantly occur due to age, performance status, adverse reactions and other reasons, resulting in the modification of the chemotherapy dose intensity. The present review analyzed the correlation between the chemotherapy dose intensity and the incidence of adverse reactions, the treatment efficacy and disease prognosis in clinical trials of metastatic colorectal cancer. Moreover, the clinical applications of chemotherapy dose intensity were discussed. Based on individual differences, the present review analyzed the clinical trials that examined the efficacy of the chemotherapy dose intensity in different patient populations. The conclusions suggested that different populations require a specific dose intensity to reduce treatment toxicity without affecting the curative effect. Contents 1. Introduction 2. Three-drug combination chemotherapy regimens 3. Two-drug combination chemotherapy regimens 4. DI of specific populations 5. Conclusion

show abstract

Update in version 2021 of CSCO guidelines for colorectal cancer from version 2020

Cited by 41 publications

References 40 publications

Better prognostic determination of cT3 rectal cancer through measurement of distance to mesorectal fascia: A multicenter study

Better prognostic determination of cT3 rectal cancer through measurement of distance to mesorectal fascia: A multicenter study

The Association Between Dietary Intake and Improvement of LARS Among Rectal Cancer Patients After Sphincter-Saving Surgery-A Descriptive Cohort Study

Management of chemotherapy dose intensity for metastatic colorectal cancer (Review)

Contact Info

Product

Resources

About